300
Participants
Start Date
October 31, 2012
Primary Completion Date
April 30, 2013
Study Completion Date
April 30, 2013
3.50±0.25logCCID50/ml
Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
4.25±0.25 logCCID50/ml
Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
5.00±0.25 logCCID50/ml
Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
0 logCCID50/ml
0 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1)
Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in children (2-4 years old) and infants (8-23 months old) on day 0.
Hebei Provincial Center for Diseases Control and Prevention, Shijiazhuang
Hebei Provincial Center for Diseases Control and Prevention
UNKNOWN
Institute of Medical Biology, Chinese Academy of Medical Sciences
OTHER